TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07606950: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-5635 Injection in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patien

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 540 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07606950 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07606950 Rescue Dossier →